1-(2'-pyridyl)benzo-1,2,3-triazole, also known as **PBT**, is a heterocyclic organic compound with a specific structure. It consists of a benzo-1,2,3-triazole ring system with a 2-pyridyl group attached to the nitrogen atom at position 1.
**Importance in research:**
PBT has gained significant attention in various research areas due to its unique properties and potential applications:
**1. Click Chemistry:**
- PBT is a valuable reagent in click chemistry, a powerful tool for synthesizing complex molecules by joining smaller building blocks.
- It readily undergoes a copper-catalyzed azide-alkyne cycloaddition (CuAAC) reaction with azide-containing molecules, forming stable triazole linkages.
**2. Bioconjugation:**
- Its click chemistry capabilities make PBT a versatile tool for bioconjugation, the process of attaching molecules to biological targets.
- It can be used to label proteins, antibodies, and other biomolecules with fluorescent dyes, radioactive isotopes, or other functionalities for imaging, tracking, and diagnostic purposes.
**3. Materials Science:**
- PBT can be incorporated into polymers, nanoparticles, and other materials to enhance their properties.
- Its presence can improve thermal stability, mechanical strength, and biocompatibility of materials.
**4. Drug Discovery:**
- PBT and its derivatives have shown promise as potential drug candidates.
- The triazole ring and the pyridine moiety provide structural motifs that can interact with biological targets, leading to therapeutic effects.
**5. Supramolecular Chemistry:**
- PBT's ability to form strong hydrogen bonds and other non-covalent interactions makes it suitable for constructing supramolecular assemblies, which are important in fields like self-assembly and nanotechnology.
**Overall, 1-(2'-pyridyl)benzo-1,2,3-triazole (PBT) is a versatile compound with a wide range of applications in chemistry, biology, materials science, and medicine. Its unique properties, including its click chemistry reactivity and ability to form stable triazole linkages, make it a valuable tool for research and development.**
1-(2'-pyridyl)benzo-1,2,3-triazole: RN is from 9th CI, Chem Subs Index; cpd not in Chemline 9/9/82 [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
ID Source | ID |
---|---|
PubMed CID | 151802 |
CHEMBL ID | 1380042 |
SCHEMBL ID | 678640 |
MeSH ID | M0053554 |
Synonym |
---|
OPREA1_870601 , |
smr000037244 |
MLS000038150 |
1-(pyridin-2-yl)-1h-benzotriazole |
STK059875 |
AKOS003671433 |
1-pyridin-2-ylbenzotriazole |
1-(2'-pyridyl)benzo-1,2,3-triazole |
13174-93-1 |
1h-benzotriazole, 1-(2-pyridinyl)- |
HMS2166K11 |
FT-0674192 |
1-(2-pyridinyl)benzotriazole |
HMS3311F20 |
SCHEMBL678640 |
1-(pyridin-2-yl)-1h-1,2,3-benzotriazole |
AE-842/00014040 |
1-(2-pyridinyl)-1h-1,2,3-benzotriazole |
CHEMBL1380042 |
DTXSID70157191 |
CPWBWUGSSFRASR-UHFFFAOYSA-N |
1-(pyridin-2-yl)-1h-benzo[d][1,2,3]triazole |
1-(2-pyridyl)benzotriazole |
CS-0321042 |
Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
---|---|---|---|---|---|---|---|
Chain A, Beta-lactamase | Escherichia coli K-12 | Potency | 0.7079 | 0.0447 | 17.8581 | 100.0000 | AID485294 |
Luciferase | Photinus pyralis (common eastern firefly) | Potency | 37.9330 | 0.0072 | 15.7588 | 89.3584 | AID588342 |
ATAD5 protein, partial | Homo sapiens (human) | Potency | 20.5962 | 0.0041 | 10.8903 | 31.5287 | AID504467 |
P53 | Homo sapiens (human) | Potency | 22.3872 | 0.0731 | 9.6858 | 31.6228 | AID504706 |
vitamin D3 receptor isoform VDRA | Homo sapiens (human) | Potency | 89.1251 | 0.3548 | 28.0659 | 89.1251 | AID504847 |
chromobox protein homolog 1 | Homo sapiens (human) | Potency | 79.4328 | 0.0060 | 26.1688 | 89.1251 | AID540317 |
nuclear factor erythroid 2-related factor 2 isoform 2 | Homo sapiens (human) | Potency | 29.0929 | 0.0041 | 9.9848 | 25.9290 | AID504444 |
ras-related protein Rab-9A | Homo sapiens (human) | Potency | 3.5481 | 0.0002 | 2.6215 | 31.4954 | AID485297 |
DNA polymerase iota isoform a (long) | Homo sapiens (human) | Potency | 39.8107 | 0.0501 | 27.0736 | 89.1251 | AID588590 |
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] |
Assay ID | Title | Year | Journal | Article |
---|---|---|---|---|
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID504810 | Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID504812 | Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
AID1745845 | Primary qHTS for Inhibitors of ATXN expression | |||
AID651635 | Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression | |||
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (20.00) | 29.6817 |
2010's | 3 (60.00) | 24.3611 |
2020's | 1 (20.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.56) All Compounds (24.57) |
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 5 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |